Engaging Disparities in Prostate Cancer Care Podcast Series (2021)
Engaging Disparities in Prostate Cancer Care consists of multiple educational activities featuring a variety of formats for the urologic healthcare team to reinforce the essentials of SDM to better assist high-risk patients in regards to prostate cancer screening and treatment. A live webinar, Clinical Problem Solving (CPS) Protocol, and Podcast Series will enable participants to be better prepared to apply SDM in their practice and comply with the recently proposed USPSTF Grade C recommendation for PSA screening. The latest research documenting the benefits and drawbacks of PSA screening as well as treatment approaches for incident localized prostate cancer will be incorporated.
These educational offerings are intended for a wide-range of health practitioners, both experienced and new to the field, as well as graduate trainees. Attendees will hear, observe, evaluate and Practice SDM strategies for prostate cancer screening and treatment decisions. Activities will focus on recommended strategies for improving SDM, participants’ attitudes towards SDM, and knowledge about SDM. Attendees will return to their practices with a higher confidence level for integrating shared treatment decision making into clinical practice. All three educational activities will be available through the AUAUniversity.
These Engaging Disparities in Prostate Cancer Care Podcast Series will focus on disparities in prostate cancer in African American men and underserved communities. The Chair of the AUA Office of Education will serve as a moderator and interview a diverse faculty to gather their insights into SDM, access to care and treatment outcomes.
The 3 topic-specific podcasts will focus on the following:
- Insight into Race, SDM, and the Impact on Access to Quality Care
- Improving Racial Disparities in Treatment Outcomes
- How Can We Improve SDM From a Prostate Cancer Survivor's Perspective
Support provided by independent educational grants from:
- Bayer HealthCare Pharmaceuticals Inc.
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
- Pfizer, Inc.
- Advanced Practice Provider (Nurse Practitioners & Physician Assistants)
At the conclusion of this educational series, the learner will:
- Discuss the impact of SDM on patients and on patient-clinician communication.
- Identify at least one implementation strategy for using SDM in clinical practice.
- Apply SDM techniques in a role-playing exercise with other colleagues.
- Incorporate culturally sensitive communications to ensure quality SDM and reduce biases.
- Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.
Education Council Disclosures
Education Council Disclosures_ June 2021.pdf
COI Review Work Group Disclosures
COI Review Work Group Disclosures 2021.pdf
All relevant financial relationships have been mitigated.
AUA Office of Education Staff has nothing to disclose.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 3.0 hours
Release Date: July, 2021
Expiration Date: December, 2022
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.